Colleagues,
I am sharing a concise analysis of Cameroon’s WUENIC 2024 results with targeted, system-level recommendations. The brief synthesises a decade of trends (2015–2024), highlights equity gaps, and proposes practical fixes aligned with IA2030.
Key findings (snapshot):
-HepB birth dose remains at 0% through 2024, despite BCG at 93% indicating feasible birth-dose delivery.
-HPV first-dose coverage fell from 68% (2023) to 36% (2024); the adolescent platform needs reinforcement.
-DTP3 is 77% with a persistent 5-point DTP1→DTP3 drop-out; IPV1→IPV2 at 75%→72%, signalling completion and utilisation gaps.
-MCV2 at 49% and YFV at 74% remain below outbreak-prevention thresholds.
-MenA is absent from the routine schedule post-2011–2012 campaign, leaving new cohorts unprotected, considering emningitis belt.
-Malaria vaccine launched in 2024; early operational lessons and success emerging from Phase 1 districts.
Given these findings, what should be Cameroon’s top priorities over the next 6–36 months to close coverage and equity gaps most efficiently?
See Attachment in pdf.
Also publised on LinkedIn at https://www.linkedin.com/pulse/wuenic-2024-cameroons-immunization-paradox-revealed-tambe-vhcee
Thank you in advance for engaging.
Best regards,
Tambe Elvis Akem
Medical Field Epidemiologist & Immunization/Health Specialist
@ImmunizationForResilienceNewsletter